Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FAM in connection with the restructuring of Bergvik Skog and the formation of Kopparfors Skogar
Mandate

Vinge advises FAM in connection with the restructuring of Bergvik Skog and the formation of Kopparfors Skogar

May 31, 2019

FAM and other shareholders in Bergvik Skog AB have performed a restructuring of the ownership of Bergvik Skog whereupon, among other things, Bergvik Skog Väst AB has been divided up and one of FAM wholly‑owned subsidiaries, Kopparfors Skogar AB, has acquired through a subsidiary approximately 283 000 hectares of land in central Sweden. 

FAM was advised by Vinge, the team of which primarily consisted of Jonas Johansson, Joacim Rydergård, Carl Sander and Jesper Lindvall (Corporate/M&A), Assur Badur and Karolina Cohrs (Real Estate), Thomas Sjöberg (Environmental), Louise Brorsson Salomon (Financing) and Johan Wahlbom (Competition Law).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026